scanX
Sun Pharmaceutical

Sun Pharmaceutical

1,629.70
-77.00
(-4.51%)
ann
Q1 Quarterly Results are out. Check out the updated financials1 day ago
Viewcross
right
Market Cap
3,91,019.60 Cr
EPS
45.60
PE Ratio
34.07
Dividend Yield
0.98 %
Industry
Healthcare
52 Week High
1,960.35
52 Week Low
1,553.05
PB Ratio
5.41
Debt to Equity
0.04
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from36 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+80.56 %
+80.56 %
Hold
Hold+11.11 %
+11.11 %
Sell
Sell+8.33 %
+8.33 %

Company News

View All News
Caret
negative
Sun Pharma Shares Drop 4% After Trump Demands Drug Price Cuts from Major Pharmaceutical Companies2 days ago
Sun Pharma shares declined 4% after initially falling 6%, leading losses in the Nifty Pharma index following US President Donald Trump's letters to 17 major pharmaceutical companies demanding lower drug prices. Trump's letter required companies to charge the US similar rates to other countries for new medicines and lower Medicaid costs for existing drugs, with 60 days given for voluntary compliance. Sun Pharma derives around 20% of its revenues from innovative drugs sold in the US and had not received such communication as of their last quarterly conference call. The Trump administration is seeking most favoured nation treatment for Medicaid pricing to match rates charged in other wealthy developed nations. Other pharmaceutical stocks also declined, with Aurobindo Pharma, Gland and Granules India falling 2-3%. Most Indian generic companies face limited impact as they don't sell branded generics or innovator drugs.
positive
Sun Pharma Plans Unloxcyt Launch for Advanced Skin Cancer Treatment2 days ago
Sun Pharma aims to release Unloxcyt, a treatment for advanced skin cancer, in the second half of FY '26. The launch is contingent upon receiving FDA approval for the drug.
positive
Sun Pharma Reports Strong FY25 Performance with 9% Revenue Growth, Announces Leadership Transition2 days ago
Sun Pharmaceutical Industries held its 33rd Annual General Meeting on July 31, 2025, via video conferencing. The company reported strong financial performance for FY25 with revenue growing 9.0% to ₹520 billion, EBITDA increasing 17.3% to ₹153 billion with 29% margin, and adjusted net profit rising 19.0% to ₹120 billion. Global Specialty Revenue grew 17.1% to US$1,216 million, contributing 20% of total revenue. India Formulation Sales increased 13.7% to ₹169 billion, while US Sales rose 5.8% to ₹162 billion. The company launched Leqselvi for severe alopecia areata in the US and completed acquisition of Checkpoint Therapeutics. Shareholders approved several resolutions including appointment of Vidhi Shanghvi as Whole-time Director and Kirti Ganorkar as Managing Director. Chairman Dilip Shanghvi announced his transition from Managing Director role, with Ganorkar taking over the position. The company declared a final dividend of Rs. 5.50 per equity share for FY 2024-25 and expects mid to high single-digit topline growth for FY26.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,629.70
#1 3,91,019.60
#6 34.07
#1 54,729.00
#7 9.71
#1 10,980
#10 -19.84
36.52
Divis Laboratories
6,361.50
1,68,877.80
77.07
9,712.00
0.89
2,191
23.05
30.87
Torrent Pharmaceuticals
3,678.20
1,24,487.00
61.58
11,539.40
6.99
1,911
19.91
66.62
Cipla
1,502.80
1,21,382.30
22.49
28,409.50
7.12
5,291
9.88
48.02
Mankind Pharma
2,566.30
1,05,918.60
55.95
12,744.20
#1 20.90
2,007
-18.14
54.69
Dr Reddys Laboratories
1,220.60
1,01,867.70
#1 17.92
33,741.20
16.73
5,725
1.26
35.90
Zydus Life Science
949.05
95,496.60
20.54
23,511.00
13.82
4,615
-0.19
40.50
Lupin
1,867.30
85,278.70
26.24
22,909.50
19.94
3,306
#1 112.49
37.22
Abbott
33,595.00
71,387.00
50.58
6,684.70
10.80
1,414
27.83
48.05
Aurobindo Pharma
1,079.80
62,715.00
18.15
31,378.10
17.55
3,366
-0.50
36.97
Forecast
Actual
Growth Rate
Revenue Growth
9.71 %
Net Income Growth
13.80 %
Cash Flow Change
15.96 %
ROE
5.43 %
ROCE
14.46 %
EBITDA Margin (Avg.)
9.26 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
6,493
6,691
6,973
7,260
7,622
8,164
7,869
7,805
7,050
6,319
6,845
6,727
7,014
7,339
7,198
7,850
7,326
8,472
8,150
8,159
8,180
7,640
9,019
9,124
8,575
9,822
9,780
10,247
9,500
10,646
10,894
11,274
11,099
11,990
12,297
12,407
12,419
13,057
13,618
13,903
13,429
14,251
Expenses
5,318
5,679
5,000
4,877
5,382
5,335
5,092
5,472
5,590
6,064
5,275
5,200
5,294
5,618
6,621
5,587
6,147
6,379
6,334
6,314
7,083
9,375
6,360
6,431
7,147
7,529
6,996
7,257
11,042
7,877
7,996
8,237
8,300
8,932
9,013
8,974
9,049
9,045
9,352
9,983
9,604
10,368
EBITDA
1,175
1,012
1,973
2,383
2,240
2,829
2,776
2,333
1,460
255
1,570
1,528
1,720
1,721
577
2,263
1,179
2,094
1,816
1,845
1,098
-1,736
2,659
2,693
1,427
2,293
2,784
2,990
-1,542
2,769
2,899
3,037
2,799
3,058
3,284
3,433
3,370
4,012
4,266
3,920
3,824
3,883
Operating Profit %
13 %
13 %
27 %
31 %
27 %
33 %
34 %
29 %
18 %
2 %
20 %
21 %
21 %
21 %
3 %
27 %
13 %
23 %
20 %
21 %
12 %
-25 %
25 %
27 %
16 %
22 %
27 %
26 %
-18 %
26 %
26 %
26 %
23 %
24 %
25 %
26 %
23 %
28 %
29 %
26 %
25 %
25 %
Depreciation
462
240
258
251
288
316
304
307
338
347
359
339
455
402
427
471
454
457
473
547
575
496
499
532
554
503
530
554
557
588
610
660
672
651
633
622
650
655
626
631
664
701
Interest
135
135
158
128
103
135
54
167
45
109
157
95
155
131
130
145
150
104
84
63
52
52
33
26
30
35
36
19
37
14
19
46
93
81
49
35
74
62
69
52
49
75
Profit Before Tax
591
872
1,572
2,040
2,087
2,628
2,930
2,102
1,389
-159
1,114
1,148
1,376
1,274
112
1,730
694
1,647
1,433
1,351
577
-2,184
2,206
2,163
903
1,804
2,287
2,466
-2,076
2,285
2,412
2,472
2,240
2,481
2,791
3,000
2,816
3,424
3,598
3,476
3,254
3,173
Tax
-596
115
272
100
424
360
458
380
3
164
113
792
-187
88
272
269
-26
151
270
332
85
242
263
250
61
400
200
340
152
191
157
291
257
476
406
440
157
563
561
563
1,100
880
Net Profit
1,186
757
1,299
1,940
1,663
2,268
2,471
1,722
1,386
-323
1,002
356
1,563
1,186
-160
1,461
721
1,497
1,163
1,019
493
-2,426
1,943
1,913
842
1,404
2,086
2,126
-2,227
2,093
2,256
2,181
1,983
2,006
2,385
2,561
2,659
2,861
3,037
2,913
2,154
2,293
EPS in ₹
3.70
2.30
4.30
6.40
5.90
8.50
9.30
6.10
5.20
-1.77
3.80
1.34
5.60
4.41
-1.12
5.18
2.65
5.78
4.43
3.81
1.67
-6.90
7.56
7.72
3.70
6.00
8.50
8.60
-9.50
8.60
9.40
9.00
8.30
8.40
9.90
10.50
11.10
11.80
12.70
12.10
9.00
9.50
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
49,028
55,530
61,410
64,516
64,694
68,253
67,667
69,808
80,744
85,500
92,101
Fixed Assets
12,683
15,872
17,675
18,853
21,837
22,847
21,553
22,665
24,065
23,248
22,586
Current Assets
29,122
29,941
32,954
31,636
31,069
31,654
30,442
34,865
39,862
43,433
52,594
Capital Work in Progress
2,039
2,175
2,801
2,465
1,411
1,220
1,567
1,287
4,973
5,354
6,644
Investments
2,117
1,830
1,192
7,143
7,903
10,143
9,612
12,849
14,824
15,026
18,354
Other Assets
32,189
35,653
39,742
36,056
33,544
34,042
34,935
33,007
36,881
41,872
44,517
Total Liabilities
49,028
55,530
61,410
64,516
64,694
68,253
67,667
69,808
80,744
85,500
92,101
Current Liabilities
16,353
13,144
17,887
19,864
17,340
15,706
16,146
17,208
19,906
16,984
18,194
Non Current Liabilities
4,186
5,319
3,093
2,454
2,632
3,421
2,041
1,533
1,522
1,390
1,420
Total Equity
28,489
37,068
40,431
42,198
44,723
49,125
49,480
51,066
59,316
67,126
72,486
Reserve & Surplus
25,383
32,741
36,400
38,074
41,169
45,025
46,223
47,771
55,755
63,427
71,978
Share Capital
207
241
240
240
240
240
240
240
240
240
240
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
2,927
848
611
-736
-844
-1,386
596
-1,765
116
4,662
983
Investing Activities
-1,502
-3,949
-4,186
-3,104
-310
-2,225
407
-5,556
-7,220
-763
-5,183
Operating Activities
5,616
6,686
7,082
3,907
2,196
6,555
6,170
8,985
4,959
12,135
14,072
Financing Activities
-1,187
-1,889
-2,285
-1,539
-2,731
-5,715
-5,981
-5,194
2,376
-6,710
-7,906
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
16.79 %
0.00 %
17.72 %
17.23 %
18.02 %
18.05 %
17.96 %
17.26 %
DIIs
21.59 %
21.93 %
21.67 %
20.94 %
19.94 %
19.57 %
18.60 %
19.14 %
19.24 %
19.75 %
19.67 %
17.97 %
18.83 %
19.28 %
18.61 %
18.55 %
18.70 %
19.50 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.34 %
7.21 %
6.79 %
6.68 %
6.49 %
6.31 %
5.91 %
5.76 %
5.70 %
5.65 %
5.56 %
5.41 %
5.44 %
5.57 %
5.43 %
5.47 %
5.42 %
5.35 %
Others
16.60 %
16.38 %
17.05 %
17.90 %
19.09 %
19.64 %
21.01 %
20.63 %
20.58 %
20.12 %
3.51 %
22.13 %
3.53 %
3.44 %
3.46 %
3.46 %
3.45 %
3.42 %
No of Share Holders
0
7,09,045
7,57,366
6,75,908
6,80,800
6,62,384
6,47,167
6,43,512
6,25,252
6,24,561
6,16,588
6,12,626
6,31,392
6,73,217
6,57,317
6,89,623
7,04,983
7,23,770

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3.5 2 2.75 4 7.5 10 11.5 13.5 16
Dividend Yield (%) 0.00 0.71 0.42 0.78 0.67 0.82 1.01 0.71 0.78 0.98

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
31 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 31 Jul 2025 1,731.60 1,734.95
31 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jul 2025 1,663.15 1,734.95
07 Jul 2025 DIVIDEND Dividend
₹ 5.50 /share
 07 Jul 2025 1,731.60 1,676.65
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 22 May 2025 1,744.85 1,731.60
06 Feb 2025 DIVIDEND Dividend
₹ 10.50 /share
 06 Feb 2025 1,739.10 1,753.40
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jan 2025 1,756.85 1,739.10
21 Jan 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
 21 Jan 2025 1,806.20 1,778.25
28 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 28 Oct 2024 1,916.85 1,860.40
05 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 05 Aug 2024 1,520.65 1,731.65
12 Jul 2024 DIVIDEND Dividend
₹ 5.00 /share
 12 Jul 2024 1,541.15 1,583.25
09 Feb 2024 DIVIDEND Dividend
₹ 8.50 /share
 09 Feb 2024 1,371.60 1,500.25
28 Jul 2023 DIVIDEND Dividend
₹ 4.00 /share
 28 Jul 2023 945.00 1,134.95
08 Feb 2023 DIVIDEND Dividend
₹ 7.50 /share
 08 Feb 2023 1,050.90 1,005.65
22 Aug 2022 DIVIDEND Dividend
₹ 3.00 /share
 19 Aug 2022 903.90 901.35
10 Feb 2022 DIVIDEND Dividend
₹ 7.00 /share
 09 Feb 2022 827.35 886.45
25 Aug 2021 DIVIDEND Dividend
₹ 2.00 /share
 23 Aug 2021 703.80 771.35
10 Feb 2021 DIVIDEND Dividend
₹ 5.50 /share
 09 Feb 2021 564.35 623.60

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication1 day ago
Rumour verification - Regulation 30(11)1 day ago
Clarification sought from Sun Pharmaceutical Industries Ltd1 day ago
Sun Pharmas Q1FY26 Investor Call Audio Recording2 days ago
Shareholder Meeting / Postal Ballot-Outcome of AGM2 days ago
Financial Results For The Quarter Ended 30 June 20252 days ago
Board Meeting Outcome for Outcome Of The Board Meeting2 days ago
Execution Of Settlement Agreement In The In Re Generic Pharmaceuticals Pricing Antitrust Litigation9 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 15, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Sun Pharma Announces Launch Of LEQSELVI™ In The USJul 14, 2025
Sun Pharma Announces Settlement On LEQSELVI™Jul 14, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Q1 Of FY 2025-26Jul 11, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 10, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 04, 2025
Notice For 33Rd Annual General Meeting Of Sun Pharmaceutical Industries LimitedJul 04, 2025
Reg. 34 (1) Annual Report.Jul 04, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 24, 2025
Update On US FDA Halol InspectionJun 14, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJun 13, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jun 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 29, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 23, 2025
Investor Audio Call RecordingMay 22, 2025
Intimation Of Record Date For The Purpose Of Final DividendMay 22, 2025
Audited Financial Results For The Quarter And Year Ended 31 March 2025May 22, 2025
Intimation Regarding Appointment Of Secretarial AuditorMay 22, 2025
Corporate Action-Board approves DividendMay 22, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 22, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 12, 2025
Board Meeting Intimation for Approval Of Audited Financial Results For The Year Ended 31 March 2025 And Final Dividend If AnyMay 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Order Vacating Preliminary Injunction On LEQSELVI™Apr 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Apr 02, 2025

Technical Indicators

RSI(14)
Neutral
36.52
ATR(14)
Volatile
32.35
STOCH(9,6)
Neutral
55.66
STOCH RSI(14)
Neutral
44.82
MACD(12,26)
Bearish
-2.12
ADX(14)
Weak Trend
19.25
UO(9)
Bearish
44.68
ROC(12)
Downtrend And Accelerating
-5.66
WillR(14)
Oversold
-84.50
Bearish
3
Neutral
6
Bullish
0

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
UTI Nifty200 Momentum 30 Index Fund Direct - Growth
0.00%
-2330823
-4.85%
-5.52%
Kotak Arbitrage Fund Direct-Growth
0.72%
1323700
0.30%
0.28%
ICICI Prudential India Opportunities Fund Direct - Growth
4.48%
1141367
0.47%
0.98%
ICICI Prudential Equity & Debt Fund Direct-Growth
4.41%
1057126
0.26%
0.72%
JM Flexicap Fund Direct Plan-Growth
0.00%
-700000
-1.98%
-2.61%
ICICI Prudential Value Direct-Growth
3.89%
564973
0.06%
-0.30%
ICICI Prudential Equity Arbitrage Direct-Growth
0.58%
535850
0.27%
0.23%
Quant ELSS Tax Saver Fund Direct-Growth
0.62%
442935
0.62%
0.62%
HDFC Arbitrage Fund Wholesale Direct-Growth
0.59%
441350
0.35%
0.29%
SBI Arbitrage Opportunities Fund Direct-Growth
0.33%
439950
0.18%
0.19%
Aditya Birla Sun Life Quant Fund Direct-Growth
0.98%
-338371
-2.37%
-2.69%
SBI Large Cap Direct Plan-Growth
1.36%
-316418
-0.15%
-0.33%
HDFC Manufacturing Fund Direct - Growth
4.13%
-300000
-0.45%
-1.34%
UTI Multi Asset Allocation Fund Direct-Growth
2.42%
282450
0.74%
0.57%
Motilal Oswal Nifty 200 Momentum 30 Index Fund Direct - Growth
0.00%
-264802
-4.85%
-5.52%
ICICI Prudential Multi Asset Fund Direct-Growth
1.49%
263791
0.01%
-0.12%
HDFC NIFTY200 Momentum 30 Index Fund Direct-Growth
0.00%
-214227
-4.85%
-5.52%
Axis ELSS Tax Saver Direct Plan-Growth
1.58%
-213830
-0.14%
-0.43%
ICICI Prudential Bharat Consumption Fund Direct - Growth
3.11%
200000
1.07%
0.83%
UTI ELSS Tax Saver Fund Direct-Growth
0.86%
200000
0.86%
0.86%
Bandhan Flexi Cap Fund Direct-Growth
2.42%
200000
0.37%
0.76%
Motilal Oswal Balanced Advantage Fund Direct-Growth
0.00%
-200000
-3.63%
-2.03%
ICICI Prudential Large Cap Fund Direct-Growth
2.66%
179084
-0.06%
-0.26%
Axis Arbitrage Fund Direct-Growth
0.45%
164850
0.40%
0.44%
ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct - Growth
0.00%
-159517
-4.85%
-5.52%

About Sun Pharmaceutical

Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun Pharma has a strong presence in India and the US, which account for about 70% of its revenue. It operates 43 manufacturing facilities worldwide and invests 7-8% of revenue in R&D annually. The company has expanded through acquisitions and licensing deals to strengthen its specialty and generic portfolios. Key specialty products include Ilumya, Winlevi, Cequa and others in dermatology, ophthalmology and oncology. Sun Pharma supplies medicines to over 100 countries and has manufacturing facilities across six continents.
Website
https://www.sunpharma.com
Chairperson NameDilip S Shanghvi
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Intraday Screeners
Fundamental Screeners
Candlestick Screeners
Technical Screeners
Price & Volume Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104